News
CMMB
1.240
-3.12%
-0.040
Weekly Report: what happened at CMMB last week (0317-0321)?
Weekly Report · 4h ago
Chemomab Therapeutics Updates ADS Offering Under Sales Agreement
TipRanks · 3d ago
Weekly Report: what happened at CMMB last week (0310-0314)?
Weekly Report · 03/17 11:31
Weekly Report: what happened at CMMB last week (0303-0307)?
Weekly Report · 03/10 11:33
Chemomab Therapeutics Reports 2024 Financial Results and Progress
TipRanks · 03/07 04:15
Chemomab Therapeutics Presents New Data Highlighting Clinical Potential Of Its Nebokitug In Systemic Sclerosis At CORA 2025 Conference
Benzinga · 03/06 13:48
Chemomab Therapeutics announces new scientific presentation on nebokitug
TipRanks · 03/06 13:11
Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer
TipRanks · 03/04 13:15
Chemomab Therapeutics GAAP EPS of -$0.01
Seeking Alpha · 03/03 14:23
Chemomab Therapeutics Reports 2024 Financial Results and Advances PSC Treatment
TipRanks · 03/03 13:29
Chemomab Therapeutics sees cash runway through 1Q26
TipRanks · 03/03 13:05
CHEMOMAB THERAPEUTICS LTD: Q4 SHR LOSS LESS THAN $0.01
Reuters · 03/03 13:00
Weekly Report: what happened at CMMB last week (0224-0228)?
Weekly Report · 03/03 11:32
Weekly Report: what happened at CMMB last week (0217-0221)?
Weekly Report · 02/24 11:31
Chemomab Therapeutics Price Target Raised to $7.00/Share From $4.00 by Maxim Group
Dow Jones · 02/20 18:36
Chemomab Therapeutics Is Maintained at Buy by Maxim Group
Dow Jones · 02/20 18:36
Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7
Benzinga · 02/20 18:26
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
TipRanks · 02/20 13:10
Chemomab Therapeutics (CMMB) Receives a Buy from Oppenheimer
TipRanks · 02/19 13:17
Chemomab Aligns with FDA on Phase 3 Trial Path for PSC Drug
TipRanks · 02/19 12:27
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.